Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saunders Kevin O, Lee Esther, Parks Robert, Martinez David R, Li Dapeng, Chen Haiyan, Edwards Robert J, Gobeil Sophie, Barr Maggie, Mansouri Katayoun, Alam S Munir, Sutherland Laura L, Cai Fangping, Sanzone Aja M, Berry Madison, Manne Kartik, Bock Kevin W, Minai Mahnaz, Nagata Bianca M, Kapingidza Anyway B, Azoitei Mihai, Tse Longping V, Scobey Trevor D, Spreng Rachel L, Rountree R Wes, DeMarco C Todd, Denny Thomas N, Woods Christopher W, Petzold Elizabeth W, Tang Juanjie, Oguin Thomas H, Sempowski Gregory D, Gagne Matthew, Douek Daniel C, Tomai Mark A, Fox Christopher B, Seder Robert, Wiehe Kevin, Weissman Drew, Pardi Norbert, Golding Hana, Khurana Surender, Acharya Priyamvada, Andersen Hanne, Lewis Mark G, Moore Ian N, Montefiori David C, Baric Ralph S, Haynes Barton F
Аннотация
Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2)1-4. Vaccines that elicit protective immunity against SARS-CoV-2 and betacoronaviruses that circulate in animals have the potential to prevent future pandemics. Here we show that the immunization of macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, and adjuvanted with 3M-052 and alum, elicits cross-neutralizing antibody responses against bat coronaviruses, SARS-CoV and SARS-CoV-2 (including the B.1.1.7, P.1 and B.1.351 variants). Vaccination of macaques with these nanoparticles resulted in a 50% inhibitory reciprocal serum dilution (ID50) neutralization titre of 47,216 (geometric mean) for SARS-CoV-2, as well as in protection against SARS-CoV-2 in the upper and lower respiratory tracts. Nucleoside-modified mRNAs that encode a stabilized transmembrane spike or monomeric receptor-binding domain also induced cross-neutralizing antibody responses against SARS-CoV and bat coronaviruses, albeit at lower titres than achieved with the nanoparticles. These results demonstrate that current mRNA-based vaccines may provide some protection from future outbreaks of zoonotic betacoronaviruses, and provide a multimeric protein platform for the further development of vaccines against multiple (or all) betacoronaviruses.